This inventor holds 19 USPTO granted patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Takeda Pharmaceutical Company Limited, Takeda San Diego, Inc.. Active years: 2007-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2007-2018
Areas of Expertise:
Title: Unveiling the Innovations of Inventor Anthony R. Gangloff from San Diego, CA
Introduction:
Anthony R. Gangloff, a prolific inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals with a total of 19 patents to his name. His groundbreaking work in developing heteroarylamide inhibitors of TBK1 showcases his commitment to advancing medical treatment options.
Latest Patents:
Gangloff's latest patents revolve around compounds of formula 1, which serve as potent inhibitors of TBK1. These compounds have paved the way for the creation of pharmaceutical compositions aimed at treating conditions associated with TBK1. Furthermore, the innovative processes for manufacturing these compounds and their intermediates highlight Gangloff's expertise in drug development.
Career Highlights:
With a rich professional background, Gangloff has lent his expertise to renowned companies such as Takeda Pharmaceutical Company Limited and Takeda San Diego, Inc. His involvement in these organizations has undoubtedly played a pivotal role in shaping the pharmaceutical landscape, solidifying his reputation as a forward-thinker in the industry.
Collaborations:
Throughout his career, Gangloff has collaborated closely with esteemed colleagues like Andrew John Jennings and Jason W. Brown. These collaborations have not only fostered a culture of innovation but have also led to the successful realization of complex pharmaceutical projects, underscoring the power of teamwork in driving meaningful advancements.
Conclusion:
In conclusion, Anthony R. Gangloff's unwavering dedication to innovation and his relentless pursuit of scientific excellence have undeniably left an indelible mark on the world of pharmaceuticals. His pioneering work in developing inhibitors of TBK1 continues to be a source of inspiration for aspiring inventors and researchers alike, reaffirming his status as a trailblazer in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile